



New Warning on Intelence

August 26, 2009 By [Paul Dalton](#)

The FDA has issued a new safety warning for the NNRTI Intelence (etravirine). The text reads:

August 2009

Dear Healthcare Professional:

Tibotec Therapeutics, in cooperation with the U.S. Food and Drug Administration, would like to inform you of an important safety update to the Severe Skin Reactions WARNINGS AND PRECAUTIONS section (5.1) of the INTELENCE (etravirine) tablets prescribing information.

Specifically, the existing Warning and Precaution regarding Severe Skin Reactions has been strengthened to reflect that there have been postmarketing reports of:

? fatality due to toxic epidermal necrolysis

**? hypersensitivity reactions, sometimes
accompanied by hepatic failure**

**Additionally, Guidance has been added that
INTELENCE should be immediately discontinued
when signs and symptoms of severe skin or
hypersensitivity reactions develop. Given the
clinical relevance of these adverse reactions, the
following information regarding severe skin and
hypersensitivity reactions has been included in
the INTELENCE Prescribing Information**

These kinds of reactions have been seen with other drugs in this class.

Intelece (aka worst HIV drug name ever) is a second line NNRTI for use in people whose HIV has developed resistance to other NNRTIs, like Sustiva (efavirenz) and Virmune (niravapine).

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/blog/new-warning-on-intel>